


Community Conversation

Patients Leading the Way: How PEDDLE is
Shaping the Future of MASH Trials

Community Conversation Agenda

- Overview of the Liver Forum
 - Sehyr Khan, Forum for Collaborative Research
- Overview of Patient Engagement
 - Michael Betel, Fatty Liver Alliance
- MASH POWER Council
 - Rosemarie Sellati, Regeneron
- Patient Engagement at Madrigal
 - Chris Frates, Madrigal Pharmaceuticals
- Patient Engagement in the Regulatory Context
 - Henry Chang, Fatty Liver Foundation
- What is PEDDLE Doing?
 - Michael Betel, Fatty Liver Alliance



Overview of the Liver Forum

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.

Overview of the Forum for Collaborative Research

The Forum for Collaborative Research, a public/private partnership and part of the UC Berkeley School of Public Health, has addressed cutting-edge regulatory science and policy issues for over 20 years through a process of stakeholder engagement and deliberation.

Review

A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials

Raluca Pais^{1,2}, Bertrand Cariou³, Mazen Nouredin⁴, Sven Francque^{5,6}, Jörn M. Schattenberg⁷, Manal F. Abdelmalek⁸, Gadi Lalazar⁹, Sharat Varma¹⁰, Julie Dietrich¹¹, Veronica Miller¹², Arun Sanyal¹³, Vlad Ratziu^{1,14,*}, on behalf of the Liver Forum NAFLD-Associated Comorbidities Working Group

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.

POSITION PAPER

Twenty-five years of addressing cutting-edge scientific, policy, and regulatory issues through collaboration: The Forum for Collaborative Research

Robin Schaefer¹ | Alessi Ayvaz² | Christopher R. Hoffman³ | Margot Yann⁴ | Zachary Rooney⁵ | Mitchell Leus⁶ | Shilpa Mitra⁷ | Veronica Miller⁸ | for the Forum for Collaborative Research

JOURNAL ARTICLE

Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes

Marion G Peters¹, Man-Fung Yuen, Norah Terrault, John Fry, Pietro Lampertico, Ed Gane, Carey Hwang, Luisa M Stamm, Mitchell Leus, Mala K Maini, Patricia Mendez, Isabelle Lonjon-Domanec, Thomas Berg, Su Wang, Poonam Mishra, Eric Donaldson, Stephanie Buchholz, Veronica Miller², Oliver Lenz on behalf of the HBV Forum Stopping Finite Therapy Working Group
Author Notes

Clinical Infectious Diseases, Volume 78, Issue 4, 15 April 2024, Pages 983–990,
<https://doi.org/10.1093/cid/ciad506>

Published: 26 August 2023 Article history ▼



JOURNAL ARTICLE

Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum

Per Ljungman¹, Roy F Chemaly, Fareed Khawaya, Sophie Alain, Robin Avery, Cyrus Badshah, Michael Boeckh, Martha Fournier, Aimee Hodowanec, Takashi Komatsu, Ajit P Limaye, Oriol Manuel, Yoichiro Natori, David Navarro, Andreas Pikis, Raymund R Razonable, Gabriel Westman, Veronica Miller, Paul D Griffiths, Camille N Kotton, for the CMV Definitions Working Group of the Transplant Associated Virus Infections Forum

SPECIAL ARTICLE

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science

Siddiqui, Mohammad Shadab^{1,†}; Harrison, Stephen A.^{2,†}; Abdelmalek, Manal F.³; Anstee, Quentin M.⁴; Bedossa, Pierre⁵; Castera, Laurent⁶; Dimick-Santos, Lara⁷; Friedman, Scott L.⁸; Greene, Katherine¹⁴; Kleiner, David E.⁹; Megnien, Sophie¹⁰; Neuschwander-Tetri, Brent A.¹¹; Ratziu, Vlad¹²; Schabel, Elmer¹³; Miller, Veronica¹⁴; Sanyal, Arun J.¹; on behalf of the Liver Forum Case Definitions Working Group

Author Information

Hepatology 67(5):p 2001-2012, May 2018. | DOI: 10.1002/hep.29607

OPEN

OPINION

Promising results of HIV prevention trials highlight the benefits of collaboration in global health: The perspective of the Forum HIV Recency Assay Working Group

Robin Schaefer^{1,*}, Logan Donaldson¹, Mitchell Leus¹, Chukwunonso E. Osakwe¹, Benjamin Chimukangara², Shona Dalal³, Ann Duerr⁴, Fei Gao⁴, David V. Glidden⁵, Beatriz Grinsztejn⁶, Jessica Justman⁷, Grace Kumwenda⁸, Oliver Laeyendecker⁹, Ha Youn Lee¹⁰, Frank Maldarelli¹¹, Kenneth H. Mayer^{12,13}, Jeffrey Murray¹⁴, Bharat S. Parekh¹⁵, Brian Rice¹⁶, Michael N. Robertson¹⁷, Suzue Saito¹⁷, Vani Vannappagari¹⁸, Mitchell Warren¹⁹, Diana Zeballos²⁰, Jörg Zinslerling²¹, Veronica Miller¹

Berkeley Public Health

THE FORUM
For Collaborative Research™

Ocular Diseases Forum 2

Saturday, September 28, 2024
University of California, Washington Center
1608 Rhode Island Avenue NW, Washington DC 20036
AGENDA


AASLD
The Liver Meeting™

Overview of the Liver Forum

- **What:** a platform for ongoing multi-stakeholder dialogue to identify barriers, prioritize research and identify solutions to accelerate therapeutic development for MASLD/MASH
- **How:** provide a neutral, independent, safe space for discussion and deliberation across stakeholder groups
 - Focus on developing consensus, increasing synergy and collaboration, and reducing duplication and uncertainty
 - Ongoing working group activity throughout the year anchored by larger project events twice yearly
 - Active & engaged participation



Liver Forum Steering Committee



Liver Forum Sponsors

89bio

AGED
DIAGNOSTICS

akero

altimmune

AMRA

AstraZeneca

Boehringer
Ingelheim

BOSTON
Pharmaceuticals

Chemomab
THERAPEUTICS

EA Pharma Co., Ltd.

echosens

ENYO
PHARMA

escopics
ULTRASOUND AGILITY

Fortrea

Galectin
Therapeutics

GILEAD

GSK

HepaRegeniX
delivering recovery

HEPAQUANT
FUNCTION MATTERS

HIGHTIDE

HISTOINDEX®
New Standard | New Life

ICON

Intercept

inventiva

IPSEN
Innovation for patient care

Janssen
Pharmaceutical Companies of
Johnson & Johnson

Lilly

Madrigal
Pharmaceuticals

MERCK
INVENTING FOR LIFE

mirum

NORDIC BIOSCIENCE

northsea
THERAPEUTICS

novo nordisk®

Oncoustics

PathAI

Pfizer

PHARMANEST
DIGITAL PATHOLOGY

PLIANT
THERAPEUTICS

prosciento
ADVISE • ADVANCE • ACHIEVE

PSC PARTNERS
SEEKING A CURE
pscpartners.org

RECTIFY
PHARMA

REGENERON
SCIENCE TO MEDICINE®

Takeda

TERNIS
PHARMACEUTICALS

The Liver
Meeting®

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for use.

The Forum Team

Veronica Miller – Director & Faculty Lead

Program Leads and Project Managers

- Robin Schaefer – Postdoctoral Scholar
- Logan Donaldson – Research Associate
- Sehyr Khan – Research Associate
- Mitchell Leus – Research Associate
- Shilpa Mitra – Research Associate
- Ekene Osakwe – Research Associate
- Edyth Dwyer – Research Associate

Data & Analysis Center

- Chris Hoffman – IT and Operational Director
- Margot Yann – Lead Data Scientist
- Mengxi Bai – Research Data Analyst
- Zachary Rooney – Technical & Infrastructure Lead

Administration

- Donna Dahrouge – Assist. Director, Administration
- Christopher Berry – Sr Events and Operations Manager
- Donnice Butler – Sr Admin Assistant
- Alicia Jellinek – Program Financial Analyst
- Jordan Cathey – Development Consultant

Program Advisors

- Claire M. Gelfman – Program Advisor
- Richard Haubrich – Program Advisor
- Jeffrey S. Murray – Program Advisor
- Mike Robertson – Program Advisor
- John Sninsky – Program Advisor

Student Assistants

- Roma Ranade – Graduate Student Assistant
- Kathy An – Undergraduate Student Assistant
- Alessi Ayvaz – Undergraduate Student Assistant
- Allison Li – Undergraduate Student Assistant


Ongoing Working Group Efforts

- Combination Therapy
 - Dr. Alina Allen, Mayo Clinic & Dr. Michelle Long, Novo Nordisk
- Patient Engagement in Drug Development: Leading Through Example (PEDDLE)
 - Mr. Michael Betel, Fatty Liver Alliance & Mr. Henry Chang, Fatty Liver Foundation & Mrs. Rosemarie Sellati, Regeneron
- Pediatric MASH
 - Dr. Stavra Xanthakos, Cincinnati Children's Hospital Medical Center & Dr. Miriam Vos, Emory University
- Pooling of Endpoints
 - Dr. Jasmohan Bajaj, VCU & Dr. Michelle Long, Novo Nordisk
- MetALD/ALD
 - Dr. Maja Thiele, Odense University & Dr. Nikhil Vergis, GSK
- NITs for RLSE
 - Dr. Richard Haubrich, Forum for Collaborative Research & UC San Diego

What is PEDDLE?

- Launched at Liver Forum 17 on September 4, 2024
- Aims to put patients at the core of MASH clinical development
- Assess the current landscape of patient engagement
- Discuss common hurdles with industry and patient engagement
- Establish touchpoints with regulators





Patient Engagement

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.

Patient Engagement

What is it?

“Patient engagement is the meaningful involvement of patients, caregivers, and the healthcare community at large throughout the research process, from planning and design to implementation and dissemination of results. This engagement ensures that the perspectives and experiences of patients drive research priorities, study design, and outcomes.”



Patient-Centered Outcomes Research Institute



Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.

Patient Engagement Examples

1. Real-World Symptom Tracking and Lifestyle Integration
2. Including Mental Health and Behavioral Support Metrics
3. Reducing the Burden of Invasive Procedures
4. Diverse Representation in MASH Trials

Patient Engagement Examples

1. Real-World Symptom Tracking and Lifestyle Integration

- MASH patients often report symptoms like fatigue and brain fog that may not be captured. Engaging patients in trial design helps ensure these symptoms are considered.
 - help add symptom-tracking measures and patient-reported outcomes
 - make trials more relevant to patient experiences and provide a fuller picture of therapeutic impact.

Patient Engagement Examples

2. Including Mental Health and Behavioral Support Metrics

- Many MASH patients experience stress, anxiety, and lifestyle challenges related to diet and exercise regimens. Patients have advocated for the inclusion of mental health assessments and behavioral support metrics as part of the trial.
 - patient input has led to the inclusion of mental health evaluations and support components (access to nutritional or psychological counseling)
 - helps evaluate the full impact of the treatment

Patient Engagement Examples

3. Reducing the Burden of Invasive Procedures

- Engaging patients in trial design has led to the reduction of certain invasive procedures, such as liver biopsies, and the inclusion of non-invasive liver assessments like FibroScan
 - MASH trials include imaging technologies like MRI-PDFF or FibroScan, allowing more comfortable and accessible liver assessments
 - shift may have been largely driven by patient feedback on reducing procedure-related stress and enhancing convenience

Patient Engagement Examples

4. Diverse Representation in MASH Trials


- Given the prevalence of MASH among those with type-2 diabetes and obesity, patient engagement has highlighted the need for trials to include a more diverse population representing varying metabolic profiles, ethnic backgrounds, and lifestyle factors.
 - trials in the MASH space increasingly incorporate input from diverse patient groups
 - study populations better reflect the broad demographics of those affected by MASH
 - provides more generalizable and equitable data

Patient Engagement Practical Strategies

1. Forming Patient Steering Committees and Advisory Boards
2. Patient Friendly Trial Materials and Processes
3. Incorporating Tool and Technology
4. Recognizing and Addressing Health Literacy Levels
5. Sharing Trial Results with Participants

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.





MASH POWER Council

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.

Value of Early Patient Engagement

“New standard” led by regulators, legislatures, advocacy groups

“The informed, empowered patient is becoming the norm.” - Drug Information Association (DIA)

- Transformational approach to identifying and responding to the unmet needs of patients worldwide
- Global movement building since early 2010s
- Benefits to **patients**, **sponsors** and **society**
- More meaningful clinical trials with **increased feasibility**, **enhanced recruitment / retention**, and real-world **outcomes**
- **FDA Guidance** provides new details on **Diversity Action Plans** required for certain clinical studies

- [Food and Drug Administration](#)
- [European Medicines Agency](#)
- [DIA Patient Engagement](#)
- [National Institute for Health Research](#)
- [National Health Council](#)
- [Patient-Centered Outcomes Research Institute](#)
- [European Patients’ Academy on Therapeutic Innovation](#)



Value of Early Patient Engagement

Not just the “right thing” to do

Patient engagement impacts the bottom line

Financial Value of Patient Engagement Study Results¹

3 Months

Earlier launch

25%

Reduction in enrollment time

\$65M

Calculated median financial impact

1. Impact of a patient engagement activity in Phase 2 Trial that avoids one protocol amendment and improves enrollment, adherence, and retention Bennett Levitan, MD, PhD,1 Kenneth Getz, MBA,2 Eric L. Eisenstein, DBA,3 Michelle Goldberg, MBA,4 Matthew Harker, MPH, MBA,5 Sharon Hesterlee, PhD,6 Bray Patrick-Lake, MFS,7 Jamie N. Roberts, MPH, MA,7 and Joseph DiMasi, PhD2 *Assessing the Financial Value of Patient Engagement*, 2017

Clinical Trial Transformation Initiative

Dozens of case studies show:

- Quantifiable impact on **revenue, cost, time**
- Powerful expression of **good corporate citizenship**
- Improvement in **trial design/execution**
- Reduction in study **risks/mitigation** of conflicts of interest




50 percent of confirmatory Phase III trials fail. (Applied Clinical Trials, April 2016)

Estimates vary on the cost of a failed clinical trial, but figures range anywhere from **\$800 million to \$1.4 billion** (FDA)



TOTAL MEDIAN DIRECT COST FOR A SUBSTANTIAL AMENDMENT:
Phase II and Phase III protocols
\$141,000 & \$535,000



Case Study-MASH POWER Council

POWER=Patient Organizations Who Empower Results

Overall Goals

- Establish a **Patient Advocate Council** with members representing different perspectives
- Provide **ongoing patient expertise and insights** to inform Regeneron MASH Program strategy
- Disseminate findings to **advance the field of study**


Key Objectives

- Map the **patient journey**, from symptomology through disease management, to define the patient experience from a humanistic perspective
- Identify **barriers to clinical trial participation**, including differences for subpopulations
- Understand **community engagement** models in rural and underserved regions
- Identify high impact opportunities to publish and **share Council insights**
- Build **meaningful collaborations** with patients, caregivers, and community members

Output

- Deliverables include a **patient journey map**, an **educational infographic**, **video testimonials**, and a planned **publication**

Council members providing specific expertise



Case Study-MASH POWER Council

The Council provided insights into awareness and motivation challenges, informing opportunities for meaningful engagement with Hispanic and Latino communities

Lack of Urgency

- HCPs often do not **effectively communicate the severity** of the disease, so patients may not understand the urgency to seek treatment or enroll in clinical trials
- Patients prioritize **managing their comorbid conditions** (e.g., diabetes, obesity, kidney disease, cardiovascular disease) as a more imminent need

Unawareness

- Patients are often not diagnosed until they are late stage and **ineligible for trials** due to a lack of HCP awareness
- There are **few channels** for patients to become aware of clinical trials; notable ones include **HCPs and Patient Groups**

Mistrust

- Marginalized populations may experience a deep mistrust of the healthcare system and clinical trials due to a **history of exploitation and mistreatment**
- The COVID-19 pandemic and anti-vaccination movement reinforced the fear, suspicion, and mistrust of the healthcare system

Cultural Challenges

- Patients may be motivated to enroll in a clinical trial, but receive push-back from their community, because pharma and HCPs are viewed as **“outsiders”**
- In some cultures, the use of **traditional medicine or healing** is encouraged over “Western medicine”


“Not putting the unmet medical needs of patients first, early in the development process, can lead to wrong priorities, wrong decisions on research design, and potentially costly late-stage failure.” – Clinical Trials Transformation Initiative (CTTI)

THANK YOU

**Regeneron plans to continue engaging with the
MASH POWER Council and sharing insights
with the broader community**

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.





Patient Engagement at Madrigal

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.

Christopher Frates

Vice President, Corporate Communications and
Patient Advocacy, Madrigal Pharmaceuticals

Disclosure: Madrigal employee



Patient Engagement at Madrigal

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for MASH

- Madrigal developed the first medication for MASH with moderate to advanced fibrosis to receive accelerated approval from the FDA
- Madrigal has worked closely with the MASH patient advocacy community to gather insights about the burden of MASH and support disease education



Photos from an August 2024 Patient Advocacy Summit hosted by Madrigal

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.

Madrigal Organized a Listening Session that Explored Research Priorities for the Patient Community



Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.

Madrigal Organized a Listening Session that Explored Research Priorities for the MASH Patient Community

What we heard from patient advocates:

- Seek patient input early
- Move away from biopsy
- Improve diversity in clinical trials
 - Extend reach into underserved communities, both rural and urban
- Accelerate research in the pediatric MASH population



Patient Engagement Challenges and Opportunities: Industry Perspective

Challenges

Patient input is valued, but process for collecting isn't always standardized

Patient advocacy function may not exist at smaller companies; may be 'siloed' in larger ones


Hard for many patients to attend conferences like The Liver Meeting due to cost of travel

Opportunities

Toolkit to define how and when to collect patient input on a development program

Build a more expansive understanding of patient advocacy's role in biopharma


Establish grants/scholarships to support larger patient presence at medical meetings



Patient Engagement in the Regulatory Context

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.

Patient Engagement in the Regulatory Context



Henry E. Chang
Co-Chair, PEDDLE Working Group, Liver Forum
Executive Director, Fatty Liver Foundation
henry@fattyLiverfoundation.org

Co-Creation of Patient-Centric Trial Protocols and Informed Consent Forms



ENGAGEMENT ROLE

Patients and patient advocates collaborate with study sponsors during the protocol development phase (e.g. Phase IIb and III) to ensure trial designs reflect patient priorities and minimize burdens.



IMPACT

For MASH trials, this might include advocating for the use of non-invasive diagnostic tools (e.g., imaging or biomarkers) instead of liver biopsies. Patients can also provide feedback on visit frequency, transportation needs, and other logistical barriers that affect enrollment and retention.



REGULATORY RELEVANCE

The U.S. FDA encourages trial designs that reduce barriers and promote patient-focused outcomes, aligning with patient-centric drug development principles.

Collaborating on Diversity Action Plans (DAPs) → Ensuring Inclusive Study Design



ENGAGEMENT ROLE

Patients and patient advocates collaborate with sponsors to co-develop DAPs, addressing barriers to participation for underrepresented populations disproportionately affected by MASLD/MASH, including Hispanic/Latino, Native Americans, Asian Americans, African Americans, and low-income populations facing systemic healthcare disparities.



IMPACT

Improves the inclusivity of recruitment strategies, ensuring diverse populations are adequately represented in MASH clinical trials.



REGULATORY RELEVANCE

Aligns with the Food and Drug Omnibus Reform Act (FDORA) of 2022 requirements for DAPs, enhancing FDA compliance and promoting equitable representation in MASH drug development.

Collaborating on Diversity Action Plans (DAPs) → Community Outreach and Education



ENGAGEMENT ROLE

Advocacy groups engage with underrepresented communities to build trust, address misconceptions about clinical trials, and highlight the importance of diverse participation in MASH research.



IMPACT

Increases awareness, enrollment, and retention in clinical trials while fostering a sense of ownership and inclusion among diverse patient populations.



REGULATORY RELEVANCE

Supports FDA goals for diversity and inclusivity in clinical trials, contributing to the robustness of trial data for regulatory review.

Collaborating on Diversity Action Plans (DAPs)

→ Feedback on Enrollment Goals



ENGAGEMENT ROLE

Patients and patient advocates review and provide input on DAP enrollment targets to ensure they are realistic, culturally appropriate, and address real-world barriers like language, transportation, and childcare.



IMPACT

Ensures that recruitment plans are practical and tailored to patient needs, improving the likelihood of meeting diversity goals.




REGULATORY RELEVANCE

Helps sponsors create actionable, FDA-compliant DAPs that strengthen the credibility and applicability of trial outcomes.



PEDDLE Next Steps




Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.

What does PEDDLE want to accomplish?

1. Establish Regular Working Group Meetings
 - collaborative sessions with deliverables
2. Develop and Promote Consensus on the Value of Patient Engagement
 - create a unified stance
3. Link Patient Engagement to Scientific and Economic Outcomes
 - build evidence
4. Create Tangible Deliverables for Stakeholders
 - whitepapers, guidelines

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.





Thank You!

Slides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.